89bio to Participate in the Leerink Partners Global Healthcare Conference
89bio (Nasdaq: ETNB), a clinical-stage biopharmaceutical company specializing in liver and cardiometabolic disease therapies, has announced its upcoming participation in the Leerink Partners Global Healthcare Conference.
The company's management will engage in a fireside chat on Monday, March 10, 2025, at 4:20 PM EST, alongside one-on-one investor meetings. Investors can access the webcast through 89bio's website investor section, with replay availability for approximately 30 days post-conference.
89bio (Nasdaq: ETNB), un'azienda biofarmaceutica in fase clinica specializzata nelle terapie per malattie epatiche e cardiometaboliche, ha annunciato la sua prossima partecipazione alla Global Healthcare Conference di Leerink Partners.
Il management dell'azienda parteciperà a un fireside chat lunedì 10 marzo 2025, alle 16:20 EST, insieme a incontri individuali con gli investitori. Gli investitori possono accedere alla trasmissione in diretta attraverso la sezione investitori del sito web di 89bio, con disponibilità della registrazione per circa 30 giorni dopo la conferenza.
89bio (Nasdaq: ETNB), una empresa biofarmacéutica en etapa clínica especializada en terapias para enfermedades hepáticas y cardiometabólicas, ha anunciado su próxima participación en la Conferencia Global de Atención Médica de Leerink Partners.
La dirección de la empresa participará en un fireside chat el lunes 10 de marzo de 2025, a las 4:20 PM EST, junto con reuniones individuales con inversores. Los inversores pueden acceder a la transmisión web a través de la sección de inversores del sitio web de 89bio, con disponibilidad de repetición durante aproximadamente 30 días después de la conferencia.
89bio (Nasdaq: ETNB), 간 및 심혈관 대사 질환 치료를 전문으로 하는 임상 단계의 생명공학 회사가 리어링크 파트너스 글로벌 헬스케어 컨퍼런스에 참가할 것이라고 발표했습니다.
회사의 경영진은 2025년 3월 10일 월요일 오후 4시 20분 EST에 진행되는 파이어사이드 챗에 참여하며, 투자자와의 일대일 미팅도 진행합니다. 투자자들은 89bio 웹사이트의 투자자 섹션을 통해 웹캐스트에 접근할 수 있으며, 컨퍼런스 후 약 30일 동안 재생이 가능합니다.
89bio (Nasdaq: ETNB), une entreprise biopharmaceutique en phase clinique spécialisée dans les thérapies pour les maladies hépatiques et cardiométaboliques, a annoncé sa prochaine participation à la Conférence Mondiale sur la Santé de Leerink Partners.
La direction de l'entreprise participera à un fireside chat le lundi 10 mars 2025, à 16h20 EST, ainsi qu'à des réunions individuelles avec des investisseurs. Les investisseurs peuvent accéder au webinaire via la section investisseurs du site web de 89bio, avec une disponibilité de rediffusion pendant environ 30 jours après la conférence.
89bio (Nasdaq: ETNB), ein klinisches Biopharma-Unternehmen, das sich auf Therapien für Leber- und kardiometabolische Erkrankungen spezialisiert hat, hat seine bevorstehende Teilnahme an der Global Healthcare Conference von Leerink Partners angekündigt.
Das Management des Unternehmens wird am Montag, den 10. März 2025, um 16:20 Uhr EST an einem Fireside Chat teilnehmen, sowie an Einzelgesprächen mit Investoren. Investoren können über den Investorenbereich der Website von 89bio auf den Webcast zugreifen, mit einer Wiederholung, die etwa 30 Tage nach der Konferenz verfügbar ist.
- None.
- None.
SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Monday, March 10, 2025 at 4:20 PM EST and participate in one-on-one investor meetings.
The webcast of the fireside chat will be accessible in the investor section of 89bio’s website. A replay of the webcast will be available for approximately 30 days following the conference.
About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is in Phase 3 trials for its lead candidate, pegozafermin, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis, including patients with compensated cirrhosis, and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.
Investor Contact:
Annie Chang
89bio, Inc.
investors@89bio.com
PJ Kelleher
LifeSci Advisors, LLC
617-430-7579
pkelleher@lifesciadvisors.com
Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
FAQ
When is 89bio (ETNB) presenting at the Leerink Partners Global Healthcare Conference?
How can investors access 89bio's (ETNB) Leerink Conference presentation?
What type of meetings will 89bio (ETNB) conduct at the Leerink Healthcare Conference?
What is 89bio's (ETNB) current therapeutic focus?
